MARISSA CIARAMITARO: Open Payments
NPI 1265990394 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,102 in 82 payments from 18 companies in 2025. Trend: 2023 $1,525 · 2024 $2,020 · 2025 $2,102
Food & beverage: $2,087Consulting: $15
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $476 |
| GlaxoSmithKline, LLC. | 14 | $319 |
| CSL Behring | 9 | $197 |
| Regeneron Healthcare Solutions, Inc. | 8 | $182 |
| GENZYME CORPORATION | 6 | $136 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $121 |
| Novartis Pharmaceuticals Corporation | 6 | $118 |
| Genentech USA, Inc. | 4 | $109 |
| Lilly USA, LLC | 3 | $96 |
| BioCryst US Sales Co., LLC | 4 | $90 |
Products named: DUPIXENT, AIRSUPRA, NUCALA, FASENRA, Hizentra, XOLAIR, NEFFY, EBGLYSS.
Industry payments across AZ — which companies pay providers there.
